Ovarian cancer (OC) is the most lethal gynaecologic malignancy, with the majority of patients presenting with disseminated disease. While CT of the chest, abdomen, and pelvis remains the standard imaging modality for staging, it poses challenges in identifying and assessing the extent of disease, particularly in complex regions. 

MRI provides superior soft-tissue contrast and may be particularly useful for evaluating areas that may alter the patient’s primary treatment (primary cytoreductive surgery vs primary chemotherapy). A combined approach with both imaging techniques enhances the ability to detect and stage disease, streamlining patients into appropriate treatment pathways early, which may improve patient outcomes.